Year None2022202120202019201820172016201520142013 Aug 3 View HTML version View PDF Version Regeneron Reports Second Quarter 2022 Financial and Operating Results Aug 3 View HTML version View PDF Version Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) Jul 27 View HTML version View PDF Version Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease Jul 26 View HTML version View PDF Version Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation Jul 14 View HTML version View PDF Version Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Jul 6 View HTML version View PDF Version Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022 Jul 1 View HTML version View PDF Version Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab) Jun 29 View HTML version View PDF Version EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review Jun 24 View HTML version View PDF Version Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose Jun 7 View HTML version View PDF Version FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Current page 1 Page 2 Page 3 Page 4 Page 5 Next page › Last page »